Rethinking Shingles in Children: Expert Insights for Primary Care
Shingles is increasingly being observed in healthy, immunocompetent children. Elizabeth Swanson, MD, discusses how to recognize and respond.
Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits
A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.
Bionic Pancreas for Type 1 Diabetes Found Feasible to Implement in Primary Care
The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.
Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings
Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.
Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update
Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.
Hand, Foot, and Mouth Disease Update: A Conversation with Elizabeth Swanson, MD
Elizabeth Swanson, MD, discusses the changing face of HFMD, focusing on the increasingly prevalent coxsackievirus A6 strain and its unique characteristics
Cardiovascular Health Maintained Over Time Linked to Reduced Risk of Neurodegenerative Disease, Study Suggests
Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.
JiaDe Yu, MD: When to Refer Pediatric Patients with Suspected Contact Dermatitis
In an interview at AAD 2025, Dr Yu emphasized the importance of managing contact dermatitis early and effectively to prevent long-term complications.
Elinzanetant Data to Feature Prominently at Congress of the European Society of Gynecology: Bayer Update
Elinzanetant, a first in class dual neurokinin-1 and 3 (NK-1,3) receptor antagonist in late-stage clinical development, has a US PDUFA date set for July 26, 2025.
FDA Approves Neffy 1 mg Epinephrine Nasal Spray: Daily Dose
Donanemab Treatment Linked to Increase Risk of Serious ARIA in Alzheimer Disease
Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.
Study: COVID-19 Pandemic Disruptions in Cancer Screening Show Uneven Recovery in 2023
Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.
Advances in Understanding of Itch: A Conversation with Brian S Kim, MD, MTR, at the 2025 AAD Meeting
Brian S Kim, MD, a leading investigator in the study of itch physiology, discusses the marked progress made in understanding the sensation and targeting its treatment.
Atopic Dermatitis of Childhood Onset Significantly Impacts "Life Trajectory" According to Scars of Life Survey
The impact of childhood onset AD on adult psychosocial experience, including employment and the decision to become a parent, is profound, this study reveals.
Women as Young as Age 30 May Experience Perimenopause Symptoms: Daily Dose
MENO! App, a Prescription Digital Therapeutic for Menopause, Validated in New Study
The menopausal symptom and lifestyle management app provides guideline-based CBT principles to augment hormone therapy or even to replace it for some women.
Advances in Dermatology Therapeutics: Key Insights from AAD 2025
Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.
CagriSema Phase 3 Update: Weight Loss of Nearly 16% Seen in REDEFINE 2 Trial
CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.
JiaDe Yu, MD: Key Signs of Allergic Contact Dermatitis in Children
AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.
